Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Prepaid Assets: 2020-2024

Historic Prepaid Assets for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $3.0 million.

  • SAB Biotherapeutics' Prepaid Assets fell 9.96% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 9.96%. This contributed to the annual value of $3.0 million for FY2024, which is 27.16% up from last year.
  • As of FY2024, SAB Biotherapeutics' Prepaid Assets stood at $3.0 million, which was up 27.16% from $2.3 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Prepaid Assets high stood at $3.0 million for FY2024, and its period low was $1.3 million during FY2020.
  • For the 3-year period, SAB Biotherapeutics' Prepaid Assets averaged around $2.3 million, with its median value being $2.3 million (2023).
  • As far as peak fluctuations go, SAB Biotherapeutics' Prepaid Assets soared by 106.74% in 2021, and later tumbled by 43.33% in 2022.
  • SAB Biotherapeutics' Prepaid Assets (Yearly) stood at $1.3 million in 2020, then surged by 106.74% to $2.6 million in 2021, then plummeted by 43.33% to $1.5 million in 2022, then spiked by 56.68% to $2.3 million in 2023, then grew by 27.16% to $3.0 million in 2024.